Increased leukocyte aggregation in patients with hypercholesterolaemia.

Area of Science:

• Immunology
• Cardiovascular Science
• Biochemistry

Background:

• Hypercholesterolemia is a major risk factor for cardiovascular disease.
• Leukocyte aggregation plays a role in vascular inflammation and endothelial dysfunction.
• The specific impact of elevated cholesterol on leukocyte aggregation requires further elucidation.

Purpose of the Study:

• To investigate the relationship between plasma cholesterol levels and N-formylmethionyl-leucyl-phenylalanine (FMLP)-induced leukocyte aggregation.
• To determine if elevated cholesterol is associated with increased leukocyte aggregation in hypercholesterolemia patients.

Main Methods:

• Measured FMLP-induced leukocyte aggregation in hypercholesterolemia patients (n=22) and age-/sex-matched controls (n=26).
• Stratified hypercholesterolemia patients based on plasma cholesterol levels (discriminatory level: 7.7 mmol/l).
• Analyzed correlations between leukocyte aggregation and plasma cholesterol, triglycerides, and APO-B levels.

Main Results:

• FMLP-induced leukocyte aggregation was significantly higher in hypercholesterolemia patients with plasma cholesterol >7.7 mmol/l compared to controls and those with <7.7 mmol/l.
• A significant positive correlation was observed between leukocyte aggregation and plasma cholesterol levels.
• No significant correlation was found between leukocyte aggregation and plasma triglycerides or APO-B levels.

Conclusions:

• Elevated plasma cholesterol levels are associated with increased FMLP-induced leukocyte aggregation.
• Findings support the hypothesis that high cholesterol induces cellular membrane abnormalities, leading to increased leukocyte aggregation and potential endothelial damage.
• This suggests a mechanism linking hypercholesterolemia to vascular complications through altered immune cell behavior.